NEW YORK—Biogen Idec Inc. increased the wholesale price of popular multiple-sclerosis drug Avonex by 6% last month, while Ireland's Elan Corp. gave a 7% boost to the price of MS therapy Tysabri, which it sells with Biogen.
The two blockbuster drugs make up the majority of Biogen's revenue and the higher prices continue the trend of aggressive increases for drugs that treat the debilitating disease. The moves are the second increases for both drugs in the past eight months.
A Biogen spokeswoman declined to provide a reason for the move, saying that the company doesn't comment on its pricing strategy.
via online.wsj.com
No comments:
Post a Comment